BioNTech Q3 2026 Earnings - Adjusted EPS: €1.76 -Rev: €1.29B (Est. €1.02B) -Operating Income: €125.0M -Sees Revenue FY: €1.70B to €1.90B (Previously €1.60B to €1.90B) -Still sees SG&A Expenses FYI: €700m to €800m (estimated at €761.1m) - still seeing R&D expenses FYI: €2.00B to €2.30B Buyback for $1B.